Free Trial
→ Presidential Bombshell: $150T Resource to Be Released as soon as this Summer? (From Paradigm Press) (Ad) Free ABCL Stock Alerts

AbCellera Biologics (ABCL) Financials

AbCellera Biologics logo
$4.01 -0.24 (-5.65%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$4.07 +0.06 (+1.50%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for AbCellera Biologics

Annual Income Statements for AbCellera Biologics

This table shows AbCellera Biologics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -2.21 119 153 159 -146 -163
Consolidated Net Income / (Loss)		 -2.21 119 153 159 -146 -163
Net Income / (Loss) Continuing Operations		 -2.21 119 153 159 -146 -163
Total Pre-Tax Income 		-2.21 158 219 239 -174 -200
Total Operating Income		 -4.12 156 204 217 -237 -315
Total Gross Profit		 12 233 375 485 38 29
Total Revenue		 12 233 375 485 38 29
Operating Revenue		 12 233 375 485 38 29
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 16 69 171 269 275 344
Selling, General & Admin Expense		 2.75 12 42 55 61 73
Marketing Expense		 1.26 3.84 6.91 11 14 13
Research & Development Expense		 10 29 62 108 176 167
Depreciation Expense		 1.60 4.84 14 28 24 91
Other Operating Expenses / (Income)		 0.00 19 46 66 0.00 0.00
Total Other Income / (Expense), net		 1.91 -6.52 15 23 63 114
Interest & Investment Income		 0.16 0.29 3.33 16 42 38
Other Income / (Expense), net		 1.75 -6.81 11 6.51 21 76
Income Tax Expense		 0.00 39 66 81 -28 -38
Basic Earnings per Share		 ($0.01) $0.53 $0.56 $0.56 ($0.51) ($0.55)
Weighted Average Basic Shares Outstanding		 151.33M 159.20M 275.76M 285.06M 289.17M 294.33M
Diluted Earnings per Share		 ($0.01) $0.45 $0.48 $0.50 ($0.51) ($0.55)
Weighted Average Diluted Shares Outstanding		 151.33M 263.13M 318.29M 314.83M 289.17M 294.33M
Weighted Average Basic & Diluted Shares Outstanding		 - - 283.92M 287.69M 292.78M 297.99M

Quarterly Income Statements for AbCellera Biologics

This table shows AbCellera Biologics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 27 -30 -40 -30 -28 -48 -41 -37 -50 -35 -46
Consolidated Net Income / (Loss)		 27 -30 -40 -31 -29 -47 -41 -37 -51 -34 -46
Net Income / (Loss) Continuing Operations		 27 -30 -40 -31 -29 -47 -41 -37 -51 -34 -46
Total Pre-Tax Income 		47 -31 -48 -38 -39 -49 -43 -48 -63 -47 -53
Total Operating Income		 38 -38 -65 -51 -55 -66 -55 -93 -94 -73 -63
Total Gross Profit		 101 22 12 10 6.60 9.18 9.95 7.32 6.51 5.05 4.24
Total Revenue		 101 22 12 10 6.60 9.18 9.95 7.32 6.51 5.05 4.24
Operating Revenue		 101 22 12 10 6.60 9.18 9.95 7.32 6.51 5.05 4.24
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 64 59 77 61 61 75 65 101 100 78 67
Selling, General & Admin Expense		 14 13 15 16 14 16 17 20 19 16 16
Marketing Expense		 3.09 2.69 3.77 3.84 3.47 3.10 3.37 3.14 3.14 3.14 2.84
Research & Development Expense		 27 28 53 36 38 49 39 41 41 46 42
Depreciation Expense		 5.15 14 5.51 5.61 5.74 7.54 4.84 37 37 13 5.33
Total Other Income / (Expense), net		 8.85 6.37 17 13 16 17 12 45 31 26 9.68
Interest & Investment Income		 5.56 8.44 9.76 11 11 11 10 9.80 9.60 8.67 8.05
Other Income / (Expense), net		 3.30 -2.08 6.97 2.61 4.87 6.48 1.75 35 21 17 1.63
Income Tax Expense		 20 -1.52 -8.04 -7.48 -11 -1.45 -2.14 -11 -12 -13 -7.36
Basic Earnings per Share		 $0.09 ($0.10) ($0.14) ($0.11) ($0.10) ($0.16) ($0.14) ($0.13) ($0.17) ($0.11) ($0.15)
Weighted Average Basic Shares Outstanding		 285.32M 285.06M 287.77M 288.91M 289.50M 289.17M 292.72M 294.22M 294.85M 294.33M 297.69M
Diluted Earnings per Share		 $0.08 ($0.10) ($0.14) ($0.11) ($0.10) ($0.16) ($0.14) ($0.13) ($0.17) ($0.11) ($0.15)
Weighted Average Diluted Shares Outstanding		 315.82M 314.83M 287.77M 288.91M 289.50M 289.17M 292.72M 294.22M 294.85M 294.33M 297.69M
Weighted Average Basic & Diluted Shares Outstanding		 286.10M 287.69M 288.73M 289.36M 290.17M 292.78M 294.05M 294.67M 295.37M 297.99M 298.48M

Annual Cash Flow Statements for AbCellera Biologics

This table details how cash moves in and out of AbCellera Biologics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -2.89 587 -93 -86 -254 23
Net Cash From Operating Activities		 2.69 23 245 277 -44 -109
Net Cash From Continuing Operating Activities		 2.69 23 245 277 -44 -109
Net Income / (Loss) Continuing Operations		 -2.21 119 153 159 -146 -163
Consolidated Net Income / (Loss)		 -2.21 119 153 159 -146 -163
Depreciation Expense		 1.60 2.32 4.40 8.95 13 13
Amortization Expense		 0.24 2.95 13 24 18 84
Non-Cash Adjustments To Reconcile Net Income		 1.08 13 34 56 58 -17
Changes in Operating Assets and Liabilities, net		 1.97 -115 40 30 13 -26
Net Cash From Investing Activities		 -5.78 -120 -332 -353 -221 121
Net Cash From Continuing Investing Activities		 -5.78 -120 -332 -353 -221 121
Purchase of Property, Plant & Equipment		 -4.00 -9.67 -58 -71 -77 -78
Acquisitions		 0.00 -112 -42 -28 -14 -20
Purchase of Investments		 0.00 1.78 -292 -781 -1,066 -754
Sale and/or Maturity of Investments		 -1.78 0.00 28 511 911 938
Other Investing Activities, net		 0.00 0.00 33 16 25 36
Net Cash From Financing Activities		 0.20 684 -3.89 -1.63 10 13
Net Cash From Continuing Financing Activities		 0.20 684 -3.89 -1.63 10 13
Other Financing Activities, net		 0.03 90 -3.89 -1.63 10 13
Effect of Exchange Rate Changes		 0.00 - -1.43 -9.60 0.59 -2.62

Quarterly Cash Flow Statements for AbCellera Biologics

This table details how cash moves in and out of AbCellera Biologics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -417 15 -194 -13 -7.33 -39 -9.75 25 -22 30 2.94
Net Cash From Operating Activities		 -127 31 -44 20 -0.11 -20 -42 -30 -29 -8.00 -12
Net Cash From Continuing Operating Activities		 -127 31 -44 20 -0.11 -20 -42 -30 -29 -8.00 -12
Net Income / (Loss) Continuing Operations		 27 -30 -40 -31 -29 -47 -41 -37 -51 -34 -46
Consolidated Net Income / (Loss)		 27 -30 -40 -31 -29 -47 -41 -37 -51 -34 -46
Depreciation Expense		 2.53 2.74 2.86 2.95 3.06 3.88 3.16 3.45 3.83 2.10 4.41
Amortization Expense		 4.20 13 4.26 4.30 4.35 5.23 3.61 35 34 12 2.20
Non-Cash Adjustments To Reconcile Net Income		 15 16 12 16 20 11 19 -23 7.55 -20 17
Changes in Operating Assets and Liabilities, net		 -175 29 -23 28 0.80 7.76 -27 -8.04 -24 33 10
Net Cash From Investing Activities		 -282 -17 -150 -34 -13 -24 30 52 3.70 36 7.94
Net Cash From Continuing Investing Activities		 -282 -17 -150 -34 -13 -24 30 52 3.70 36 7.94
Purchase of Property, Plant & Equipment		 -13 -12 -15 -27 -20 -14 -24 -20 -19 -16 -11
Acquisitions		 -6.08 -5.91 -4.47 -2.20 -3.54 -4.04 -5.91 -4.91 -7.14 -1.67 -1.88
Purchase of Investments		 -542 -94 -395 -170 -216 -284 -254 -168 -177 -155 -171
Sale and/or Maturity of Investments		 272 92 263 160 220 268 307 233 197 202 190
Other Investing Activities, net		 6.00 2.33 2.69 5.00 7.33 10 7.17 13 9.40 6.56 1.02
Net Cash From Financing Activities		 -0.02 0.35 -0.46 0.42 6.63 3.77 2.83 2.65 3.15 4.14 5.97
Net Cash From Continuing Financing Activities		 -0.02 0.35 -0.46 0.42 6.63 3.77 2.83 2.65 3.15 4.14 5.97
Other Financing Activities, net		 -0.25 2.76 -0.46 0.42 0.07 10 2.83 0.28 0.04 12 5.97
Effect of Exchange Rate Changes		 -8.55 0.36 -0.21 0.80 -1.06 1.07 -0.78 -0.04 0.37 -2.16 0.59

Annual Balance Sheets for AbCellera Biologics

This table presents AbCellera Biologics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 1,006 1,319 1,541 1,488 1,361
Total Current Assets		 813 930 1,025 872 751
Cash & Equivalents		 594 476 387 133 156
Restricted Cash		 - 25 25 25 25
Short-Term Investments		 0.00 247 500 627 469
Accounts Receivable		 213 161 39 31 34
Other Current Assets		 5.97 21 75 56 67
Plant, Property, & Equipment, net		 18 112 0.00 0.00 0.00
Total Noncurrent Assets		 174 277 515 616 609
Long-Term Investments		 19 50 73 66 82
Goodwill		 32 48 48 48 48
Intangible Assets		 115 148 132 120 42
Other Noncurrent Operating Assets		 8.39 31 264 382 437
Total Liabilities & Shareholders' Equity		 1,006 1,319 1,541 1,488 1,361
Total Liabilities		 175 293 308 336 304
Total Current Liabilities		 103 121 118 119 77
Short-Term Debt		 13 23 44 50 8.09
Accounts Payable		 20 32 52 50 55
Current Deferred Revenue		 6.59 7.54 22 19 14
Total Noncurrent Liabilities		 72 172 189 217 228
Noncurrent Deferred Revenue		 - 27 20 8.20 5.70
Noncurrent Deferred & Payable Income Tax Liabilities		 26 37 33 31 10
Other Noncurrent Operating Liabilities		 45 107 137 178 212
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 831 1,026 1,233 1,152 1,056
Total Preferred & Common Equity		 831 1,026 1,233 1,152 1,056
Total Common Equity		 831 1,026 1,233 1,152 1,056
Common Stock		 716 758 808 874 944
Retained Earnings		 114 268 426 280 117
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.28 -1.39 -1.72 -4.38

Quarterly Balance Sheets for AbCellera Biologics

This table presents AbCellera Biologics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 1,594 1,552 1,498 1,537 1,512 1,463 1,412 1,393 1,344
Total Current Assets		 1,144 1,046 941 931 920 814 772 743 765
Cash & Equivalents		 791 372 193 180 172 124 148 127 159
Restricted Cash		 25 25 25 25 25 25 25 25 25
Short-Term Investments		 232 496 603 616 613 574 522 516 446
Accounts Receivable		 53 106 20 46 37 34 36 31 40
Other Current Assets		 44 46 99 64 71 57 40 43 95
Plant, Property, & Equipment, net		 149 201 233 260 277 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 301 306 324 347 315 649 641 650 579
Long-Term Investments		 66 67 58 59 63 72 76 84 82
Goodwill		 48 48 48 48 48 48 48 48 48
Intangible Assets		 143 143 129 127 124 119 86 53 41
Other Noncurrent Operating Assets		 44 49 90 113 81 411 431 465 409
Total Liabilities & Shareholders' Equity		 1,594 1,552 1,498 1,537 1,512 1,463 1,412 1,393 1,344
Total Liabilities		 381 302 289 342 329 333 302 315 321
Total Current Liabilities		 221 106 90 119 110 105 70 80 75
Short-Term Debt		 34 33 43 55 54 51 20 20 8.77
Accounts Payable		 24 26 32 52 36 43 44 54 48
Current Deferred Revenue		 4.62 6.82 12 8.54 18 11 6.40 5.58 19
Total Noncurrent Liabilities		 160 196 200 223 219 228 231 235 246
Noncurrent Deferred Revenue		 - - 25 28 16 8.57 7.97 8.10 14
Noncurrent Deferred & Payable Income Tax Liabilities		 35 34 33 33 33 30 22 13 10
Other Noncurrent Operating Liabilities		 125 162 141 163 170 189 201 214 222
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,213 1,250 1,209 1,195 1,183 1,130 1,111 1,078 1,023
Total Preferred & Common Equity		 1,213 1,250 1,209 1,195 1,183 1,130 1,111 1,078 1,023
Total Common Equity		 1,213 1,250 1,209 1,195 1,183 1,130 1,111 1,078 1,023
Common Stock		 783 795 824 841 857 893 911 928 959
Retained Earnings		 429 456 386 356 327 239 202 151 71
Accumulated Other Comprehensive Income / (Loss)		 0.58 -0.72 -2.02 -1.90 -1.46 -1.82 -2.07 -1.23 -7.00

Annual Metrics And Ratios for AbCellera Biologics

This table displays calculated financial ratios and metrics derived from AbCellera Biologics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 1,907.88% 60.92% 29.38% -92.17% -24.17%
EBITDA Growth		 0.00% 29,867.05% 50.86% 9.89% -172.38% 23.47%
EBIT Growth		 0.00% 6,406.85% 44.63% 3.34% -196.98% -10.45%
NOPAT Growth		 0.00% 4,179.26% 21.76% 0.28% -215.68% -32.70%
Net Income Growth		 0.00% 5,478.47% 29.05% 3.29% -192.35% -11.24%
EPS Growth		 0.00% 4,600.00% 6.67% 4.17% -202.00% -7.84%
Operating Cash Flow Growth		 0.00% 742.24% 977.94% 13.40% -115.82% -147.41%
Free Cash Flow Firm Growth		 0.00% 0.00% 209.14% -18.56% -322.85% 10.50%
Invested Capital Growth		 0.00% 0.00% 8.60% 17.22% 19.69% -5.70%
Revenue Q/Q Growth		 0.00% 0.00% -13.63% -19.52% -24.54% -12.53%
EBITDA Q/Q Growth		 0.00% 0.00% -22.51% -30.18% -16.29% 5.88%
EBIT Q/Q Growth		 0.00% 0.00% -24.48% -35.22% -10.03% 1.68%
NOPAT Q/Q Growth		 0.00% 0.00% -30.84% -38.85% -13.53% -2.18%
Net Income Q/Q Growth		 0.00% 0.00% -27.10% -36.17% -13.36% 7.36%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -37.50% -13.33% 8.33%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -6.85% 20.73% -760.20% 9.66%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 31.28% -20.05% -0.79%
Invested Capital Q/Q Growth		 0.00% 0.00% 52.17% -9.08% -3.23% -4.28%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -4.47% 66.26% 62.12% 52.76% -487.53% -492.04%
Operating Margin		 -35.45% 66.92% 54.48% 44.60% -623.82% -1,091.69%
EBIT Margin		 -20.38% 64.00% 57.52% 45.94% -568.77% -828.45%
Profit (Net Income) Margin		 -19.04% 51.00% 40.90% 32.66% -385.00% -564.83%
Tax Burden Percent		 100.00% 75.34% 70.03% 66.30% 84.12% 81.27%
Interest Burden Percent		 93.45% 105.77% 101.54% 107.21% 80.47% 83.89%
Effective Tax Rate		 0.00% 24.66% 29.97% 33.70% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 101.98% 59.53% 52.79% -51.51% -64.56%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 101.53% 58.03% 51.04% -53.76% -72.10%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -73.34% -42.99% -38.75% 39.23% 49.82%
Return on Equity (ROE)		 0.00% 28.64% 16.53% 14.03% -12.27% -14.75%
Cash Return on Invested Capital (CROIC)		 0.00% -98.02% 51.29% 36.94% -69.43% -58.70%
Operating Return on Assets (OROA)		 0.00% 14.84% 18.57% 15.60% -14.28% -16.77%
Return on Assets (ROA)		 0.00% 11.83% 13.21% 11.09% -9.67% -11.43%
Return on Common Equity (ROCE)		 0.00% 28.64% 16.53% 14.03% -12.27% -14.75%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 14.32% 14.96% 12.85% -12.70% -15.42%
Net Operating Profit after Tax (NOPAT)		 -2.88 118 143 144 -166 -220
NOPAT Margin		 -24.82% 50.42% 38.15% 29.57% -436.67% -764.18%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.45% 1.50% 1.75% 2.26% 7.53%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 11.24% -13.80% -20.71%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 23.67% 5.11% 11.15% 11.43% 160.42% 252.18%
R&D to Revenue		 87.09% 12.61% 16.54% 22.22% 461.95% 580.10%
Operating Expenses to Revenue		 135.45% 29.51% 45.52% 55.40% 723.82% 1,191.69%
Earnings before Interest and Taxes (EBIT)		 -2.37 149 216 223 -216 -239
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.52 154 233 256 -185 -142
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 1.17 3.93 2.35 1.44 0.82
Price to Tangible Book Value (P/TBV)		 0.00 1.42 4.85 2.75 1.68 0.90
Price to Revenue (P/Rev)		 41.59 4.17 10.73 5.97 43.57 30.02
Price to Earnings (P/E)		 0.00 8.17 26.24 18.28 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 12.24% 3.81% 5.47% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1.61 12.99 6.67 2.44 0.42
Enterprise Value to Revenue (EV/Rev)		 0.00 1.59 8.67 4.03 22.51 4.88
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 2.41 13.95 7.65 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 2.49 15.06 8.78 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 3.16 22.71 13.64 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 16.39 13.29 7.06 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 26.36 19.50 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.02 0.02 0.04 0.04 0.01
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.72 -0.74 -0.76 -0.73 -0.69
Leverage Ratio		 0.00 1.21 1.25 1.27 1.27 1.29
Compound Leverage Factor		 0.00 1.28 1.27 1.36 1.02 1.08
Debt to Total Capital		 0.00% 1.59% 2.19% 3.46% 4.20% 0.76%
Short-Term Debt to Total Capital		 0.00% 1.59% 2.19% 3.46% 4.20% 0.76%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 98.41% 97.81% 96.54% 95.80% 99.24%
Debt to EBITDA		 0.00 0.09 0.10 0.17 -0.27 -0.06
Net Debt to EBITDA		 0.00 -3.88 -3.33 -3.67 4.32 5.11
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.11 0.16 0.31 -0.30 -0.04
Net Debt to NOPAT		 0.00 -5.10 -5.42 -6.55 4.82 3.29
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 5.06 10.10 7.54 3.38 1.86
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.00 7.86 7.70 8.67 7.33 9.81
Quick Ratio		 0.00 7.80 7.32 7.82 6.65 8.60
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -113 123 100 -224 -200
Operating Cash Flow to CapEx		 67.40% 234.57% 418.44% 392.53% -57.02% -138.47%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.23 0.32 0.34 0.03 0.02
Accounts Receivable Turnover		 0.00 1.09 2.01 4.87 1.10 0.90
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 13.01 5.79 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 333.82 181.82 74.88 332.04 406.40
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 333.82 181.82 74.88 332.04 406.40
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.00 231 250 293 351 331
Invested Capital Turnover		 0.00 2.02 1.56 1.79 0.12 0.08
Increase / (Decrease) in Invested Capital		 0.00 231 20 43 58 -20
Enterprise Value (EV)		 0.00 372 3,251 1,958 856 141
Market Capitalization		 483 972 4,027 2,898 1,657 865
Book Value per Share		 $0.00 $5.22 $3.64 $4.31 $3.97 $3.58
Tangible Book Value per Share		 $0.00 $4.30 $2.95 $3.68 $3.39 $3.27
Total Capital		 0.00 844 1,049 1,277 1,203 1,064
Total Debt		 0.00 13 23 44 50 8.09
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -600 -775 -940 -801 -725
Capital Expenditures (CapEx)		 4.00 9.67 58 71 77 78
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 129 84 40 18 32
Debt-free Net Working Capital (DFNWC)		 0.00 723 832 951 803 683
Net Working Capital (NWC)		 0.00 710 809 907 753 675
Net Nonoperating Expense (NNE)		 -0.67 -1.36 -10 -15 -20 -57
Net Nonoperating Obligations (NNO)		 0.00 -600 -775 -940 -801 -725
Total Depreciation and Amortization (D&A)		 1.85 5.27 17 33 31 97
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 55.38% 22.41% 8.22% 46.97% 111.79%
Debt-free Net Working Capital to Revenue		 0.00% 310.20% 221.76% 195.99% 2,112.94% 2,368.28%
Net Working Capital to Revenue		 0.00% 304.45% 215.65% 186.88% 1,980.20% 2,340.23%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.56 $0.56 ($0.51) ($0.55)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 275.76M 285.06M 289.17M 294.33M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.48 $0.50 ($0.51) ($0.55)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 318.29M 314.83M 289.17M 294.33M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 283.92M 287.69M 292.78M 297.99M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.88 118 143 144 -166 -220
Normalized NOPAT Margin		 -24.82% 50.42% 38.15% 29.57% -436.67% -764.18%
Pre Tax Income Margin		 -19.04% 67.69% 58.41% 49.26% -457.67% -695.02%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for AbCellera Biologics

This table displays calculated financial ratios and metrics derived from AbCellera Biologics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 1,740.65% -84.54% -96.15% -78.10% -93.49% -57.40% -18.36% -27.18% -1.39% -44.99% -57.45%
EBITDA Growth		 329.99% -128.40% -121.60% -1,738.29% -189.21% -106.01% 8.67% 51.96% 20.34% 17.57% -17.35%
EBIT Growth		 264.31% -148.98% -125.16% -487.75% -221.90% -49.47% 8.22% -18.87% -44.42% 6.84% -14.84%
NOPAT Growth		 209.65% -145.87% -127.64% -512.07% -278.17% -74.85% 15.38% -81.86% -70.64% -10.14% -14.15%
Net Income Growth		 224.53% -149.87% -123.79% -349.93% -207.46% -57.73% -1.25% -20.97% -78.63% 27.44% -12.34%
EPS Growth		 200.00% -150.00% -125.93% -450.00% -225.00% -60.00% 0.00% -18.18% -70.00% 31.25% -7.14%
Operating Cash Flow Growth		 -2,037.32% 284.97% -143.97% -92.71% 99.92% -163.44% 5.34% -250.56% -27,147.17% 59.21% 72.30%
Free Cash Flow Firm Growth		 25.80% -283.83% -200.98% -6,769.53% 42.48% -49.57% -0.41% 79.87% 38.09% 70.28% 143.41%
Invested Capital Growth		 96.18% 17.22% 1.98% 176.24% 12.45% 19.69% 3.88% -2.87% -4.65% -5.70% -17.28%
Revenue Q/Q Growth		 120.80% -78.75% -43.41% -17.52% -34.38% 39.08% 8.46% -26.43% -11.14% -22.41% -16.12%
EBITDA Q/Q Growth		 2,214.17% -151.29% -107.34% 18.23% -2.60% -18.43% 8.08% 56.99% -70.12% -22.56% -30.85%
EBIT Q/Q Growth		 594.35% -197.13% -45.29% 15.76% -2.53% -19.10% 10.78% -9.11% -24.57% 23.17% -9.98%
NOPAT Q/Q Growth		 466.93% -222.63% -71.72% 20.79% -6.81% -20.34% 16.90% -70.24% -0.22% 22.32% 13.88%
Net Income Q/Q Growth		 492.40% -212.28% -34.18% 23.89% 6.28% -64.80% 13.87% 9.06% -38.39% 33.06% -33.36%
EPS Q/Q Growth		 500.00% -225.00% -40.00% 21.43% 9.09% -60.00% 12.50% 7.14% -30.77% 35.29% -36.36%
Operating Cash Flow Q/Q Growth		 -146.44% 124.38% -242.54% 145.17% -100.53% -18,400.94% -112.68% 28.15% 3.62% 72.30% -44.43%
Free Cash Flow Firm Q/Q Growth		 -3,449.36% 49.12% 24.31% -417.05% 71.11% -32.31% 49.19% -3.63% 11.14% 36.48% 174.22%
Invested Capital Q/Q Growth		 140.85% -9.08% 26.86% -0.56% -1.96% -3.23% 10.09% -7.02% -3.75% -4.28% -3.42%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 47.11% -113.70% -416.56% -412.96% -645.66% -549.80% -465.96% -272.44% -521.59% -823.87% -1,285.24%
Operating Margin		 37.22% -175.36% -532.10% -511.03% -831.79% -719.70% -551.48% -1,276.17% -1,439.42% -1,440.98% -1,479.58%
EBIT Margin		 40.47% -185.00% -474.96% -485.11% -757.93% -649.05% -533.94% -791.86% -1,110.11% -1,099.17% -1,441.20%
Profit (Net Income) Margin		 26.26% -138.76% -328.99% -303.58% -433.55% -513.73% -407.98% -504.30% -785.42% -677.56% -1,077.24%
Tax Burden Percent		 57.15% 95.17% 83.31% 80.33% 72.84% 97.01% 95.00% 76.64% 81.60% 73.05% 86.10%
Interest Burden Percent		 113.54% 78.81% 83.15% 77.90% 78.53% 81.59% 80.43% 83.10% 86.71% 84.38% 86.81%
Effective Tax Rate		 42.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 52.66% -219.13% -182.89% -205.98% -85.57% -59.42% -36.40% -80.92% -93.68% -85.22% -67.75%
ROIC Less NNEP Spread (ROIC-NNEP)		 52.07% -218.73% -183.53% -206.56% -86.69% -59.32% -36.13% -84.54% -95.54% -87.41% -67.51%
Return on Net Nonoperating Assets (RNNOA)		 -40.55% 166.07% 127.51% 163.30% 62.26% 43.29% 24.40% 57.78% 65.58% 60.40% 45.35%
Return on Equity (ROE)		 12.10% -53.06% -55.38% -42.69% -23.31% -16.14% -12.00% -23.14% -28.10% -24.82% -22.40%
Cash Return on Invested Capital (CROIC)		 31.40% 36.94% -15.88% -125.98% -54.38% -69.43% -45.71% -48.74% -56.06% -58.70% -44.99%
Operating Return on Assets (OROA)		 17.92% -62.81% -55.65% -44.99% -24.92% -16.30% -12.91% -17.75% -25.19% -22.25% -23.73%
Return on Assets (ROA)		 11.63% -47.11% -38.55% -28.15% -14.26% -12.90% -9.86% -11.30% -17.82% -13.72% -17.74%
Return on Common Equity (ROCE)		 12.10% -53.06% -55.38% -42.69% -23.31% -16.14% -12.00% -23.14% -28.10% -24.82% -22.40%
Return on Equity Simple (ROE_SIMPLE)		 19.87% 0.00% -4.15% -6.19% -10.92% 0.00% -13.00% -13.80% -16.31% 0.00% -16.41%
Net Operating Profit after Tax (NOPAT)		 22 -26 -45 -36 -38 -46 -38 -65 -66 -51 -44
NOPAT Margin		 21.27% -122.75% -372.47% -357.72% -582.25% -503.79% -386.03% -893.32% -1,007.59% -1,008.68% -1,035.70%
Net Nonoperating Expense Percent (NNEP)		 0.59% -0.40% 0.63% 0.57% 1.12% -0.10% -0.28% 3.62% 1.86% 2.19% -0.24%
Return On Investment Capital (ROIC_SIMPLE)		 - -2.07% - - - -3.84% - - - -4.79% -4.25%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 13.60% 60.40% 124.13% 154.35% 217.75% 174.06% 174.32% 275.73% 294.25% 317.29% 383.14%
R&D to Revenue		 26.22% 131.11% 431.82% 362.70% 574.59% 529.76% 394.69% 558.88% 629.61% 912.58% 1,003.45%
Operating Expenses to Revenue		 62.78% 275.36% 632.10% 611.03% 931.79% 819.70% 651.48% 1,376.17% 1,539.42% 1,540.98% 1,579.58%
Earnings before Interest and Taxes (EBIT)		 41 -40 -58 -49 -50 -60 -53 -58 -72 -55 -61
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 48 -24 -51 -42 -43 -50 -46 -20 -34 -42 -54
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.26 2.35 1.79 1.56 1.13 1.44 1.16 0.78 0.71 0.82 0.65
Price to Tangible Book Value (P/TBV)		 2.66 2.75 2.10 1.83 1.32 1.68 1.36 0.89 0.78 0.90 0.71
Price to Revenue (P/Rev)		 4.68 5.97 11.98 12.85 26.41 43.57 36.73 26.33 23.24 30.02 28.75
Price to Earnings (P/E)		 11.35 18.28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 8.81% 5.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 5.86 6.67 3.58 2.81 1.41 2.44 1.48 0.33 0.10 0.42 0.00
Enterprise Value to Revenue (EV/Rev)		 3.14 4.03 7.36 7.17 10.15 22.51 15.96 3.60 1.04 4.88 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 5.16 7.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 5.50 8.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 8.06 13.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 8.24 7.06 10.02 0.00 76.92 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 24.74 19.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.03 0.04 0.04 0.05 0.05 0.04 0.05 0.02 0.02 0.01 0.01
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.78 -0.76 -0.69 -0.79 -0.72 -0.73 -0.68 -0.68 -0.69 -0.69 -0.67
Leverage Ratio		 1.24 1.27 1.28 1.30 1.26 1.27 1.27 1.28 1.28 1.29 1.30
Compound Leverage Factor		 1.40 1.00 1.06 1.01 0.99 1.04 1.02 1.06 1.11 1.09 1.13
Debt to Total Capital		 2.54% 3.46% 3.43% 4.39% 4.36% 4.20% 4.35% 1.77% 1.84% 0.76% 0.85%
Short-Term Debt to Total Capital		 2.54% 3.46% 3.43% 4.39% 4.36% 4.20% 4.35% 1.77% 1.84% 0.76% 0.85%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.46% 96.54% 96.57% 95.61% 95.64% 95.80% 95.65% 98.23% 98.16% 99.24% 99.15%
Debt to EBITDA		 0.09 0.17 -1.44 -0.79 -0.34 -0.27 -0.28 -0.13 -0.13 -0.06 -0.06
Net Debt to EBITDA		 -2.53 -3.67 28.08 11.94 5.14 4.32 4.11 4.71 4.86 5.11 4.69
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.14 0.31 -0.84 -0.67 -0.37 -0.30 -0.32 -0.11 -0.09 -0.04 -0.04
Net Debt to NOPAT		 -3.95 -6.55 16.29 10.13 5.61 4.82 4.67 3.99 3.39 3.29 3.11
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.21 6.98 5.53 4.22 3.29 3.72 3.08 2.42 2.04 2.31 1.80
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.86 8.67 10.50 7.83 8.34 7.33 7.76 10.96 9.34 9.81 10.15
Quick Ratio		 9.19 7.82 9.11 7.08 7.47 6.65 6.98 10.04 8.48 8.60 8.56
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -137 -70 -53 -272 -79 -104 -53 -55 -49 -31 23
Operating Cash Flow to CapEx		 -1,013.23% 250.71% -294.07% 73.17% -0.52% -135.89% -172.78% -149.01% -155.98% -51.18% -108.63%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.44 0.34 0.12 0.09 0.03 0.03 0.02 0.02 0.02 0.02 0.02
Accounts Receivable Turnover		 8.06 4.87 1.02 2.95 0.70 1.10 1.32 0.81 0.96 0.90 0.62
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 4.13 0.00 1.02 0.71 0.21 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 45.26 74.88 357.27 123.79 519.40 332.04 277.53 451.76 381.03 406.40 587.63
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 45.26 74.88 357.27 123.79 519.40 332.04 277.53 451.76 381.03 406.40 587.63
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 323 293 372 370 363 351 387 360 346 331 320
Invested Capital Turnover		 2.48 1.79 0.49 0.58 0.15 0.12 0.09 0.09 0.09 0.08 0.07
Increase / (Decrease) in Invested Capital		 158 43 7.23 236 40 58 14 -11 -17 -20 -67
Enterprise Value (EV)		 1,893 1,958 1,333 1,041 511 856 571 119 34 141 -39
Market Capitalization		 2,820 2,898 2,169 1,865 1,331 1,657 1,314 870 766 865 665
Book Value per Share		 $4.38 $4.31 $4.20 $4.14 $4.09 $3.97 $3.86 $3.78 $3.66 $3.58 $3.43
Tangible Book Value per Share		 $3.72 $3.68 $3.59 $3.53 $3.49 $3.39 $3.29 $3.32 $3.32 $3.27 $3.13
Total Capital		 1,283 1,277 1,251 1,250 1,237 1,203 1,181 1,131 1,098 1,064 1,032
Total Debt		 33 44 43 55 54 50 51 20 20 8.09 8.77
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -927 -940 -836 -825 -820 -801 -743 -751 -732 -725 -703
Capital Expenditures (CapEx)		 13 12 15 27 20 14 24 20 19 16 11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 79 40 72 46 52 18 37 26 15 32 68
Debt-free Net Working Capital (DFNWC)		 972 951 894 867 863 803 760 721 684 683 698
Net Working Capital (NWC)		 940 907 851 812 809 753 709 701 663 675 690
Net Nonoperating Expense (NNE)		 -5.06 3.45 -5.30 -5.44 -9.81 0.91 2.18 -28 -14 -17 1.76
Net Nonoperating Obligations (NNO)		 -927 -940 -836 -825 -820 -801 -743 -751 -732 -725 -703
Total Depreciation and Amortization (D&A)		 6.73 15 7.12 7.26 7.41 9.11 6.77 38 38 14 6.61
Debt-free, Cash-free Net Working Capital to Revenue		 13.09% 8.22% 40.02% 31.69% 103.93% 46.97% 104.71% 78.19% 46.70% 111.79% 294.57%
Debt-free Net Working Capital to Revenue		 161.17% 195.99% 493.79% 597.01% 1,713.05% 2,112.94% 2,125.06% 2,181.89% 2,073.70% 2,368.28% 3,021.34%
Net Working Capital to Revenue		 155.77% 186.88% 470.11% 559.21% 1,606.03% 1,980.20% 1,981.35% 2,121.30% 2,012.36% 2,340.23% 2,983.40%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.09 ($0.10) ($0.14) ($0.11) ($0.10) ($0.16) ($0.14) ($0.13) ($0.17) ($0.11) ($0.15)
Adjusted Weighted Average Basic Shares Outstanding		 285.32M 285.06M 287.77M 288.91M 289.50M 289.17M 292.72M 294.22M 294.85M 294.33M 297.69M
Adjusted Diluted Earnings per Share		 $0.08 ($0.10) ($0.14) ($0.11) ($0.10) ($0.16) ($0.14) ($0.13) ($0.17) ($0.11) ($0.15)
Adjusted Weighted Average Diluted Shares Outstanding		 315.82M 314.83M 287.77M 288.91M 289.50M 289.17M 292.72M 294.22M 294.85M 294.33M 297.69M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 286.10M 287.69M 288.73M 289.36M 290.17M 292.78M 294.05M 294.67M 295.37M 297.99M 298.48M
Normalized Net Operating Profit after Tax (NOPAT)		 22 -26 -45 -36 -38 -46 -38 -65 -66 -51 -44
Normalized NOPAT Margin		 21.27% -122.75% -372.47% -357.72% -582.25% -503.79% -386.03% -893.32% -1,007.59% -1,008.68% -1,035.70%
Pre Tax Income Margin		 45.95% -145.81% -394.91% -377.92% -595.18% -529.54% -429.45% -658.02% -962.53% -927.49% -1,251.10%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

AbCellera’s Q1 2025 results show continued R&D and SG&A spending alongside signs of strong liquidity and improving free cash flow. Key trends over the past year include:

  • Robust liquidity: Cash & equivalents of $159 M plus short-term investments of $446 M, supporting a current ratio above 10.
  • Net cash position: Net debt of –$703 M (negative debt), reflecting a cash-rich balance sheet.
  • Free cash flow recovery: Q1 ’25 free cash flow to firm of $22.9 M vs. –$52.9 M in Q1 ’24, driven by strong investment maturities.
  • High gross margin: 100% gross margin, consistent with a services-based model and minimal cost of revenue.
  • Continued R&D investment: R&D spending at ~10% of revenue, underscoring focus on platform development.
  • Valuation easing: Price-to-revenue multiple down to 28.7× from over 30× last quarter, modestly reducing valuation pressure.
  • Revenue decline: Q1 ’25 revenue of $4.24 M down 57% sequentially and 16% year-over-year, reflecting lower program receipts.
  • Widening net loss: Consolidated net loss of $45.6 M in Q1 ’25 vs. $40.6 M in Q1 ’24, driven by elevated operating expenses.
  • Operating cash flow remains negative: Q1 ’25 operating cash outflow of –$11.6 M, indicating ongoing cash burn.
  • Extended receivables: Days sales outstanding surged to 588 days in Q1 ’25 vs. 357 days a year earlier, tying up working capital.
07/13/25 07:02 PMAI Generated. May Contain Errors.

Frequently Asked Questions About AbCellera Biologics' Financials

When does AbCellera Biologics' fiscal year end?

According to the most recent income statement we have on file, AbCellera Biologics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has AbCellera Biologics' net income changed over the last 5 years?

AbCellera Biologics' net income appears to be on a downward trend, with a most recent value of -$162.86 million in 2024, rising from -$2.21 million in 2019. The previous period was -$146.40 million in 2023. View AbCellera Biologics' forecast to see where analysts expect AbCellera Biologics to go next.

What is AbCellera Biologics' operating income?
AbCellera Biologics' total operating income in 2024 was -$314.77 million, based on the following breakdown:
  • Total Gross Profit: $28.83 million
  • Total Operating Expenses: $343.60 million
How has AbCellera Biologics' revenue changed over the last 5 years?

Over the last 5 years, AbCellera Biologics' total revenue changed from $11.61 million in 2019 to $28.83 million in 2024, a change of 148.3%.

How much debt does AbCellera Biologics have?

AbCellera Biologics' total liabilities were at $304.47 million at the end of 2024, a 9.3% decrease from 2023, and a 74.0% increase since 2020.

How much cash does AbCellera Biologics have?

In the past 4 years, AbCellera Biologics' cash and equivalents has ranged from $133.32 million in 2023 to $594.12 million in 2020, and is currently $156.33 million as of their latest financial filing in 2024.

How has AbCellera Biologics' book value per share changed over the last 5 years?

Over the last 5 years, AbCellera Biologics' book value per share changed from 0.00 in 2019 to 3.58 in 2024, a change of 357.6%.


Related Companies

This page (NASDAQ:ABCL) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...
Paradigm Press | Sponsored
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...
Golden Portfolio | Sponsored
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...
Weiss Ratings | Sponsored
Banks aren’t ready for this altcoin—are you?
Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...
Crypto 101 Media | Sponsored